other material
confidence high
sentiment positive
materiality 0.60
FDA approves Annovis Bio's transition to new crystal form of Buntanetap for trials
Annovis Bio, Inc.
- FDA approved transition to new crystalline form of Buntanetap for future clinical trials.
- Company filed composition of matter patent for new form and provisional patent for manufacturing process in June 2024.
- Comprehensive bridge studies in solvents and animals submitted to FDA.
- FDA clearance allows a small single-dose bioavailability study in humans as part of transition.